Genomic Valley Biotech (BOM:539206) Accounts Payable: ₹0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539206 Genomic Valley Biotech Ltd BOM:539206
53 GF Score
Price ₹28.87
GF Value ₹11.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Genomic Valley Biotech Accounts Payable?

Genomic Valley Biotech BOM:539206 53 Accounts Payable is ₹0.00 Mil as of Jun. 2026. GuruFocus rates BOM:539206 with a GF Score™ of 53/100 and a GF Value™ of ₹11.28 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Genomic Valley Biotech's Accounts Payable for the quarter that ended in Jun. 2026 was ₹0.00 Mil.

Genomic Valley Biotech's quarterly Accounts Payable increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹0.06 Mil) but then declined from Mar. 2026 (₹0.06 Mil) to Jun. 2026 (₹0.00 Mil).

Genomic Valley Biotech's annual Accounts Payable declined from Mar. 2024 (₹6.02 Mil) to Mar. 2025 (₹0.10 Mil) and declined from Mar. 2025 (₹0.10 Mil) to Mar. 2026 (₹0.06 Mil).

Genomic Valley Biotech Accounts Payable Related Terms

Genomic Valley Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Genomic Valley Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech Accounts Payable Chart

Genomic Valley Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 6.11 6.02 0.10 0.06

Genomic Valley Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.04 0.00 0.06 0.00
BOM:539206
53GF Score
Genomic Valley Biotech Ltd BOM:539206
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomic Valley Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹0.00 Mil mean?
Genomic Valley Biotech (BOM:539206) has a Accounts Payable of ₹0.00 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genomic Valley Biotech and its competitors.
Is Genomic Valley Biotech's Accounts Payable too high?
Genomic Valley Biotech's current Accounts Payable is ₹0.00 Mil. Overall, Genomic Valley Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Accounts Payable compare to VRTX and REGN?
Genomic Valley Biotech's Accounts Payable of ₹0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genomic Valley Biotech and its competitors. Genomic Valley Biotech's current Accounts Payable is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.28, compared to a current price of ₹28.87 — trading 155.9% above its estimated fair value. The current Accounts Payable is ₹0.00 Mil. Genomic Valley Biotech's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Accounts Payable is ₹0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?

Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued. The current stock price of ₹28.87 is trading 155.9% above its estimated GF Value™ of ₹11.28. GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.

Key valuation signals for BOM:539206:

  • Accounts Payable: ₹0.00 Mil
  • GF Value™: ₹11.28 vs. price of ₹28.87 (155.9% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomic Valley Biotech Business Description

Address 4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
53GF Score

Get the complete analysis for BOM:539206

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹28.87
Price
₹11.28
GF Value